Pharmova’s celebratory Q2 results live: profit rises 64.48% year-on-year

Jubilant Pharmova Q2 results live: Jubilant Pharmova announced its Q2 results on October 25, 2024, showing a significant increase in profitability. The company’s revenue increased 4.28% year-over-year, while profits jumped 64.48%. Despite the positive results of the previous year, there was a slight decrease compared to the previous quarter, in which sales only grew by 1.19% and profits fell significantly by 78.68%.

Regarding costs, selling, general and administrative expenses increased 2.06% quarter-over-quarter and 6.11% year-over-year. This increase in expenses is likely to have contributed to the decline in operating income, which fell 66.98% quarter-on-quarter but recorded a year-over-year increase of 26.58%.

Earnings per share (EPS) for the second quarter were reported below ₹7.09, which represents an impressive growth of 80.04% compared to the same quarter last year. Investors might find this number encouraging as it indicates a solid increase in profitability per share.

Last week, Jubilant Pharmova suffered a slight decline, returning -5.57%. However, the company has shown remarkable recovery over time, with returns of 63.48% over the last six months and an impressive 103.14% year-to-date. This performance has resulted in a market capitalization of ₹17,551.15 Cr, with a 52-week high of ₹1247.15 and a low of ₹318.75.

Looking ahead, sentiment among analysts remains positive. As of October 26, 2024, of the three analysts covering the company, one has issued a Buy rating, while two have assigned a Strong Buy rating. The consensus recommendation is “Strong Buy,” indicating confidence in the company’s future performance.

Jubilant Pharmova financial data